Dai Fukumura

Harvard University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

108h-index57.5kcitations580works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(133), Pancreatic and Hepatic Oncology Research(118), Cancer, Hypoxia, and Metabolism(109), Cancer Cells and Metastasis(55), Cancer Immunotherapy and Biomarkers(54)

Publications579 total

Supplementary Figure S5 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
Supplementary Figure S3 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
Supplementary Figure S1 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
Supplementary Table S2 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
Supplementary Figure S7 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
Supplementary Figure S4 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
Supplementary Figure S2 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
Supplementary Table S4 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
Supplementary Table S6 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
Supplementary Table S5 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
Supplementary Figure S6 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
Supplementary Table S1 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
Supplementary Table S3 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025Open Access
TMIC-109. Wnt inhibition improves the efficacy of anti-PD-1 therapy in glioblastoma
Neuro-Oncology·2025Open Access
Wnt inhibition alleviates resistance to anti-PD1 therapy and improves antitumor immunity in glioblastoma
Proceedings of the National Academy of Sciences·2025· 3 citedOpen Access
IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity
Journal for ImmunoTherapy of Cancer·2025· 4 citedOpen Access
Tumor Microcirculation: Abnormalities and Normalization
Physiology in health and disease·2025· 1 cited
Abstract B015: Wnt inhibition improves the efficacy of anti-PD-1 therapy in glioblastoma
Cancer Immunology Research·2024· 2 cited
Supplementary Fig. S8 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
Supplementary Data from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
page 1 of 29Next →

Frequent Co-authors

Rakesh K. Jain(46), Dan G. Duda(14), Lance L. Munn(12), Lei Xu(8), Moungi G. Bawendi(8), Vikash P. Chauhan(7), John D. Martin(5), Yuhui Huang(5), Patrick Au(5), Jonas Kloepper(4), Zohreh Amoozgar(4), Ou Chen(4), Emmanuelle di Tomaso(4), Zoran Popović(4), Walid S. Kamoun(4), Timothy P. Padera(4), Meenal Datta(4), Keehoon Jung(4), Peter Carmeliet(3), Vladimir P. Torchilin(3)